Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Surgery, Orthopaedic Service, Sloan Kettering Institute, New York, New York.
J Surg Oncol. 2020 Dec;122(7):1323-1327. doi: 10.1002/jso.26170. Epub 2020 Aug 16.
Digital papillary adenocarcinoma (DPA) is a rare, aggressive neoplasm of sweat gland origin. It can recur at local, regional, or distant sites. There is limited knowledge about the role of sentinel lymph node biopsy (SLNB) in predicting recurrence in these patients. We present our experience with this uncommon tumor to evaluate the role of SLNB in predicting outcome.
Medical records of all patients who underwent surgical treatment for biopsy-proven upper extremity DPA at the study institution were reviewed. Descriptive statistics and Fisher's exact test were used to analyze data.
Twenty-one patients were identified. Most patients were male (71%), and the median age was 51 years. SLNB was performed in 18 patients; three were positive for nodal metastatic disease (17%). At a median follow-up of 53 months, there were no local recurrences and two cases of systemic recurrence. No patient with a negative sentinel lymph node has evidence of metastasis or recurrence. Fisher's exact test demonstrated a significant association between a positive SLNB and recurrence (P = .02).
SLNB revealed metastatic disease in 17% of patients with DPA and appears to predict systemic recurrence in this small series.
数字化乳头腺癌(DPA)是一种罕见的、侵袭性的汗腺来源的肿瘤。它可以在局部、区域或远处复发。关于前哨淋巴结活检(SLNB)在预测这些患者复发中的作用的知识有限。我们介绍了我们在这种罕见肿瘤中的经验,以评估 SLNB 在预测结局中的作用。
对在研究机构接受手术治疗活检证实的上肢 DPA 的所有患者的病历进行了回顾。采用描述性统计和 Fisher 确切检验对数据进行分析。
确定了 21 例患者。大多数患者为男性(71%),中位年龄为 51 岁。18 例患者进行了 SLNB;3 例患者淋巴结转移呈阳性(17%)。在中位随访 53 个月时,无局部复发和 2 例全身复发。无前哨淋巴结阴性患者有转移或复发的证据。Fisher 确切检验显示 SLNB 阳性与复发之间存在显著关联(P = .02)。
SLNB 显示 17%的 DPA 患者存在转移疾病,并且在本小系列中似乎可以预测全身复发。